Cetuximab, an anti‐EGFR chimeric monoclonal antibody, was approved for treatment in HNSCC after demonstrating an extension in survival when combined with radiotherapy in early stage disease6 and cytotoxic chemotherapy in metastatic HNSCC.7 This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.